Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW642444 dose-ascending crossover study in mild to moderate asthma
2004-002362-37Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in asthma (5 arms), sponsored by GSK. Primary endpoint: FEV1 at 24 hours after a single dose. Started Oct 2004; status: completed.
02
Drugs
vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2004-002362-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002362-37.